Metrics as of 10/13/2026, 06:33 PM (Berlin time), refresh in progress.
Spruce Biosciences Stock
Spruce Biosciences, Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Javier Szwarcberg
- Employees
- 22
- Market cap
- $111 M
- IPO
- 09/10/2020
Spruce Biosciences, Inc., founded in 2014 and situated in Daly City, California, operates as a biopharmaceutical enterprise. Its primary objective is to advance and bring to market innovative treatments, particularly for uncommon endocrine conditions. A central component of its therapeutic pipeline is tildacerfont, a…
Spruce Biosciences stock: price history
1D
-5.9%
1W
-5.7%
1M
-24.9%
6M
-40.5%
YTD
-53.7%
1Y
-74.6%
2Y
+21.2%
5Y
-89.6%
10Y
–
Next earnings date
Next earnings date
09/11/2026 (in 23 days)
Volatility around earnings
~77% stronger price swings than usual
Ask the agents about Spruce Biosciences
Analyst assessment of Spruce Biosciences
PRICE TARGET LOW
US$104.00
CONSENSUS
US$140.60
MEDIAN
US$149.00
PRICE TARGET HIGH
US$160.00
0
STRONG BUY
7
BUY
4
HOLD
0
SELL
0
STRONG SELL
11
TOTAL · Buy
As of: 24/09/2026
Spruce Biosciences stock metrics
P/E
-0.99
P/B
1.17
EV/EBITDA
-0.46
RETURN ON EQUITY
-19.4%
NET MARGIN
0.0%
DEBT/EQUITY
0.09
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
78.7%
FLOAT SHARES
2,164,942
AVG. DAILY VOLUME (30D)
100,673
Insider transactions (SEC)
Szwarcberg Javier B.
Institutional holders
Dividends & Stock splits
Comparable stocks
Frequently asked questions about Spruce Biosciences stock
What does Spruce Biosciences do?
Spruce Biosciences, Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Javier Szwarcberg, the company employs around 22 people.
The IPO was on 09/10/2020; the stock trades on NASDAQ under the ticker SPRB.
What do analysts say about Spruce Biosciences stock?
11 analysts rate the stock, the consensus is Buy (as of 24/09/2026).
The average price target is US$140.60, ranging from US$104.00 to US$160.00, with a median of US$149.00.
This is an external assessment, not a statement by Market Jury.
When does Spruce Biosciences report next?
The next earnings date is 09/11/2026.
Around past earnings, price swings were roughly 77% stronger than usual.
Does Spruce Biosciences pay a dividend?
No, Spruce Biosciences currently does not pay a dividend.
Which stocks are comparable to Spruce Biosciences?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Spruce Biosciences stock analyzed?
Clicking "Analyze stock" lets five strategies assess Spruce Biosciences against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.